pranlukast

Also found in: Wikipedia.

pranlukast

Singulair^® Allergy medicine An antileukotriene that ↓ early and late response inflammation and bronchoconstriction of asthma Effect Improved FEV₁, peak expiratory flow rate, Sx–eg, night awakening, ↓ use of β₂ agonists Mechanism LTD₄ receptor antagonism; pranlukast is used for asthma prophylaxis; it ↓ bronchial hyperresponsiveness in chronic asthma Adverse effects Zafirkulast ↑ in PT in Pts on warfarin. See Antileukotrienes, Asthma.

References in periodicals archive ?

Takeuchi, "Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate," International Journal of Pharmaceutics, vol.

Drug Method Key ingredients PSD ([micro]m) Pranlukast SD Pharmatose 200 M and <90 hydrate Pharmatose 325 M Human serum SD Albumin : lactose: DPPC 6.50 albumin (30 : 10 : 60) SS SD Lactochem crystals 7772 Budesonide SD [alpha]-LM >230 Drug Device and flow % FPF References rate (l/min) Pranlukast Spinhaler[R] 28.5 [+ or -] 3.1 [35] hydrate and 60 Human serum Spinhaler and 41 [+ or -] 5.0 [36] albumin 28.3 SS Cyclohaler and 31.3 [+ or -] 1.3 [37] 60 Budesonide Thaifun[R] 31.0 [+ or -] 5.1 [38] * Taifun is a multiple dose, reservoir-based DPI.

Imagine the Superiority of Dry Powder Inhalers from Carrier Engineering

Indeed, the CysLTR-1 antagonist pranlukast did not reduce the accumulation of microglia in the ischemic cerebral cortex [49], while HAMI 3379 significantly attenuated the number of microglia in the ischemic core and in the boundary zone [50].

Pranlukast inhibited acute, subacute, and chronic ischemic injury in the brains of mice and rats after focal cerebral ischemia [15,49,65,78].

Cysteinyl Leukotrienes as Potential Pharmacological Targets for Cerebral Diseases

employed EA.Hy926 cells to establish [H.sub.2][O.sub.2]-mediated oxidative injury model for evaluation of the protective effects of pranlukast, which was associated with the inhibition of ROS-mediated collapse of mitochondrial membrane potential [54].

Heme Oxygenase-1, a Key Enzyme for the Cytoprotective Actions of Halophenols by Upregulating Nrf2 Expression via Activating Erk1/2 and PI3K/Akt in EA.hy926 Cells

This is similar to unpublished data from our group and other studies indicating that systemic montelukast does not prevent PTZ-induced seizures in mice, as well as evidence that montelukast and pranlukast cross the BBB poorly.

Montelukast reduces seizures in pentylenetetrazol-kindled mice

Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes.

Potential inhibitory effect of 4-hydroxytoremifene on CYP2J2 activities in human liver microsomes

[7] Other treatment modalities include Altrans retinoic acid, Imatinib, Pranlukast, Cetrizine and Intravenous Immunogobulins.

Rare Kimura disease: two case reports

Pranlukast was introduced for clinical application in Japan in 1995 and is currently marketed in this and several other Asian countries.

Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function

carbama-zepina, ciclosporina, cilostazol, cisapride, clindamicina, clomipramina, clonazpam, clopidogrel, c ocaina, dapsona, dexameta- sona, dextrometorfan, diazepam, diltiazem, eritromicina, estrogenos, etosuximida, fluticasona, imipramina, indinavir, isradi- pino, ketoconazol, lansoprazol, lidocaina, lovastatina, mibefradil, midazolam, nifedi-pina, nimodipina, paricalcitol, pioglitazona, pranlukast, pravastatina, prednisolona, quinina, rifampicina, ranolaxine, repagli-nida, rimonabant, ritonavir, sertralina, sildenafil, simvastatina, sirolimus, sitaglip-tina, tacrolimus, tadalofilo, tamsulosina, terfenadina, pruebaosterona, triazolam, valdenafil, verapamilo, warfarina, zolpidem.

La farmacogenomica en medicina

Zafirlukast and pranlukast are both orally active antagonists of LTD4 and represent the furthest advanced of all the anti-leukotriene drugs currently being developed.